Is there any data to support radiation and targeted agents (Braf inhibitor or ipilimumab) combined for stage III melanoma?
Even though data from TROG 02.01 showed 52% decrease in LR, I've heard some argue that toxicity is increased and that "it damages the blood vessels and prevents targeted agents from getting into tumor"
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan Kettering Cancer Center
Answered on
Prospective trials will be reported this year at ASCO on the role of adjuvant ipilimumab (an immunotherapeutic, not a targeted therapy) for melanoma. Prospective trials of adjuvant BRAF inhibitors (vemurafenib, and others) for melanoma are ongoing (not yet reported). At present (4/25/14), there is n...
Join for free or sign in to see the full answer